Avicine, tested and developed by AVI BioPharma, and also known as CTP-37 was trialled as a possible cancer vaccine to treat a number of different cancers. These included colorectal cancer, pancreatic cancer and prostate cancer. The treatment was trialled as and intended to be induced via intramuscular injection into the bloodstream, the location dependent on the treatment area.

The Bell UH-1Y Venom (also called Super Huey) is a twin-engined, medium-sized utility helicopter, built by Bell Helicopter under the H-1 upgrade program of the United States Marine Corps. One of the latest members of the numerous Huey family, the UH-1Y is also called "Yankee", based on the NATO phonetic alphabet pronunciation of its variant letter. The UH-1Y was to have been remanufactured from UH-1Ns, but in 2005, it was approved for the aircraft to be built as new. After entering service in 2008, the UH-1Y replaced the USMC's aging fleet of UH-1N Twin Huey light utility helicopters, first introduced in the early 1970s. In 2008 it entered full-rate production, with deliveries to the Marines to be completed in late 2018.

François-Marie Bigex (24 September 1751 - 19 February 1827) was a prominent Savoyard churchman who was appointed Bishop of Ponerolo in 1817 and then, in 1824, Archbishop of Chambéry. His life and career were much affected by the French wars which impacted Savoy directly between 1792 and 1815. He spent the most dangerous years of that period exiled in Lausanne, from where he was able to direct and undertake various missionary projects designed to combat the false doctrines that had arrived with the revolutionary armies from the west. His principle weapon in these endeavours was the pen.

Avicine, tested and developed by AVI BioPharma, and also known as CTP-37 was trialled as a possible cancer vaccine to treat a number of different cancers. These included colorectal cancer, pancreatic cancer and prostate cancer. The treatment was trialled as and intended to be induced via intramuscular injection into the bloodstream, the location dependent on the treatment area. Common side effects during clinical trials included fever and chills as experienced with many other conventional vaccines. The vaccine operated by eliciting antibodies against human chorionic gonadotropin (hCG) a cancer associated protein expressed by most cancer cells, with the goal of prolonged survival for sufferers. Avicine was originated by AVI BioPharma in the USA, who licensed the product to SuperGen. However, due to delays in clinical testing, as a result of research difficulties, the owners of Avicine were forced to direct their attention to other areas being the investigation and treatment of cardiovascular and infectious disease indications.